Herein, we report the discovery that hematological cancer cells, particularly B-cell lymphomas, are highly sensitive to myristoylation inhibition by the novel pan-NMT inhibitor PCLX-001. This evidence concerns the gene NMT1 and hematopoietic and lymphoid cell neoplasm.